The Role of Metabolomics in Cervical Cancer Screening and Early Diagnosis

doi:10.12280/gjfckx.20210797

Abstract

Abstract:

Cervical cancer is the most common gynecological cancer, which is preventable and treatable. Improved screening and early detection played important role in reducing the incidence and mortality of cervical cancer. During the development of cervical cancer, there are often alterations in the type and quantity of metabolites, involving glucose metabolism, glutamine metabolism and lipid metabolism. Therefore, metabolomics has great potential in exploring mechanisms of cervical cancer initiation and development as well as new methods of screening and early detection. Through metabolite analysis of biological samples such as blood, urine, tissues and cells, we can find changes in metabolites closely related to cervical cancer and establish new screening and diagnostic methods with high sensitivity and specificity as well as convenience and good acceptability. The aim of this review is to explore the possible application of metabolomics in screening and early detection of cervical cancer.

Key words: Uterine cervical neoplasms, Metabolomics, Lipid metabolism, Amino acids, Tumor microenvironment, Early diagnosis

GE Yan-jun, ZHANG Yu-chen, WANG Xin-tao, ZHU Hai-yan. The Role of Metabolomics in Cervical Cancer Screening and Early Diagnosis[J]. Journal of International Obstetrics and Gynecology, 2022, 49(3): 302-306.

References 30

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials[J]. Lancet, 2014, 383(9916):524-532. doi: 10.1016/S0140-6736(13)62218-7. doi: 10.1016/S0140-6736(13)62218-7
[3]	Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses[J]. Vaccine, 2006, 24 (Suppl 3):S3/78-89. doi: 10.1016/j.vaccine.2006.05.117. doi: 10.1016/j.vaccine.2006.05.117
[4]	Ilhan ZE, Łaniewski P, Thomas N, et al. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling[J]. EBioMedicine, 2019, 44:675-690. doi: 10.1016/j.ebiom.2019.04.028. doi: 10.1016/j.ebiom.2019.04.028
[5]	Nam M, Seo SS, Jung S, et al. Comparable Plasma Lipid Changes in Patients with High-Grade Cervical Intraepithelial Neoplasia and Patients with Cervical Cancer[J]. J Proteome Res, 2021, 20(1):740-750. doi: 10.1021/acs.jproteome.0c00640. doi: 10.1021/acs.jproteome.0c00640
[6]	Yin MZ, Tan S, Li X, et al. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study[J]. Tumour Biol, 2016, 37(4):5485-5492. doi: 10.1007/s13277-015-4164-x. doi: 10.1007/s13277-015-4164-x
[7]	Hasim A, Aili A, Maimaiti A, et al. Plasma-free amino acid profiling of cervical cancer and cervical intraepithelial neoplasia patients and its application for early detection[J]. Mol Biol Rep, 2013, 40(10):5853-5859. doi: 10.1007/s11033-013-2691-3. doi: 10.1007/s11033-013-2691-3
[8]	Godoy-Vitorino F, Ortiz-Morales G, Romaguera J, et al. Discriminating high-risk cervical Human Papilloma Virus infections with urinary biomarkers via non-targeted GC-MS-based metabolomics[J]. PLoS One, 2018, 13(12):e0209936. doi: 10.1371/journal.pone.0209936. doi: 10.1371/journal.pone.0209936
[9]	Woo HM, Kim KM, Choi MH, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women′s cancers[J]. Clin Chim Acta, 2009, 400(1/2):63-69. doi: 10.1016/j.cca.2008.10.014. doi: 10.1016/j.cca.2008.10.014
[10]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013. doi: 10.1016/j.cell.2011.02.013
[11]	Dang CV. Links between metabolism and cancer[J]. Genes Dev, 2012, 26(9):877-890. doi: 10.1101/gad.189365.112. doi: 10.1101/gad.189365.112
[12]	Abudula A, Rouzi N, Xu L, et al. Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection[J]. Bosn J Basic Med Sci, 2020, 20(1):78-87. doi: 10.17305/bjbms.2019.4359. doi: 10.17305/bjbms.2019.4359
[13]	Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. J Gen Physiol, 1927, 8(6):519-530. doi: 10.1085/jgp.8.6.519. doi: 10.1085/jgp.8.6.519 pmid: 19872213
[14]	Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930):1029-1033. doi: 10.1126/science.1160809. doi: 10.1126/science.1160809
[15]	Yu L, Chen X, Sun X, et al. The Glycolytic Switch in Tumors: How Many Players Are Involved?[J]. J Cancer, 2017, 8(17):3430-3440. doi: 10.7150/jca.21125. doi: 10.7150/jca.21125
[16]	Chen X, Yi C, Yang MJ, et al. Metabolomics study reveals the potential evidence of metabolic reprogramming towards the Warburg effect in precancerous lesions[J]. J Cancer, 2021, 12(5):1563-1574. doi: 10.7150/jca.54252. doi: 10.7150/jca.54252 pmid: 33532002
[17]	Khan I, Nam M, Kwon M, et al. LC/MS-Based Polar Metabolite Profiling Identified Unique Biomarker Signatures for Cervical Cancer and Cervical Intraepithelial Neoplasia Using Global and Targeted Metabolomics[J]. Cancers (Basel), 2019, 11(4):511. doi: 10.3390/cancers11040511. doi: 10.3390/cancers11040511
[18]	Ward PS, Thompson CB. Signaling in control of cell growth and metabolism[J]. Cold Spring Harb Perspect Biol, 2012, 4(7):a006783. doi: 10.1101/cshperspect.a006783. doi: 10.1101/cshperspect.a006783
[19]	Chung SH, Franceschi S, Lambert PF. Estrogen and ERalpha: culprits in cervical cancer?[J]. Trends Endocrinol Metab, 2010, 21(8):504-511. doi: 10.1016/j.tem.2010.03.005. doi: 10.1016/j.tem.2010.03.005
[20]	Hasim A, Ali M, Mamtimin B, et al. Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by (1)H NMR spectroscopy[J]. Exp Ther Med, 2012, 3(6):945-951. doi: 10.3892/etm.2012.509. doi: 10.3892/etm.2012.509
[21]	Yang K, Xia B, Wang W, et al. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer[J]. Sci Rep, 2017, 7:43353. doi: 10.1038/srep43353. doi: 10.1038/srep43353
[22]	Cheng F, Wen Z, Feng X, et al. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer[J]. Life Sci, 2020, 260:118489. doi: 10.1016/j.lfs.2020.118489. doi: 10.1016/j.lfs.2020.118489
[23]	Liu Y, Wei F, Wang F, et al. Serum peptidome profiling analysis for the identification of potential biomarkers in cervical intraepithelial neoplasia patients[J]. Biochem Biophys Res Commun, 2015, 465(3):476-480. doi: 10.1016/j.bbrc.2015.08.042. doi: 10.1016/j.bbrc.2015.08.042
[24]	Chen Y, Xu J, Zhang R, et al. Assessment of data pre-processing methods for LC-MS/MS-based metabolomics of uterine cervix cancer[J]. Analyst, 2013, 138(9):2669-2677. doi: 10.1039/c3an36818a. doi: 10.1039/c3an36818a
[25]	Tokareva AO, Chagovets VV, Starodubtseva NL, et al. Feature selection for OPLS discriminant analysis of cancer tissue lipidomics data[J]. J Mass Spectrom, 2020, 55(1):e4457. doi: 10.1002/jms.4457. doi: 10.1002/jms.4457
[26]	Porcari AM, Negrão F, Tripodi GL, et al. Molecular Signatures of High-Grade Cervical Lesions[J]. Front Oncol, 2018, 8:99. doi: 10.3389/fonc.2018.00099. doi: 10.3389/fonc.2018.00099
[27]	Paraskevaidi M, Cameron S, Whelan E, et al. Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening[J]. EBio Medicine, 2020, 60:103017. doi: 10.1016/j.ebiom.2020.103017. doi: 10.1016/j.ebiom.2020.103017
[28]	Walker H, Burrell M, Flatley J, et al. A metabolite profiling method for diagnosis of precancerous cervical lesions and HPV persistence[J]. Bioanalysis, 2017, 9(8):601-608. doi: 10.4155/bio-2017-0012. doi: 10.4155/bio-2017-0012
[29]	Guerrero-Flores H, Apresa-García T, Garay-Villar Ó, et al. A non-invasive tool for detecting cervical cancer odor by trained scent dogs[J]. BMC Cancer, 2017, 17(1):79. doi: 10.1186/s12885-016-2996-4. doi: 10.1186/s12885-016-2996-4 pmid: 28122528
[30]	Rodríguez-Esquivel M, Rosales J, Castro R, et al. Volatolome of the Female Genitourinary Area: Toward the Metabolome of Cervical Cancer[J]. Arch Med Res, 2018, 49(1):27-35. doi: 10.1016/j.arcmed.2018.04.004. doi: S0188-4409(18)30103-6 pmid: 29681412